Patient disposition for patients enrolled in the expansion cohorts (parts B and D)
| . | Relatlimab monotherapy (240 mg; part B) . | Nivolumab plus relatlimab (240 mg/160 mg; part D) . | |||||
|---|---|---|---|---|---|---|---|
| CLL (n = 2) . | DLBCL (n = 2) . | IL (n = 4) . | HL∗ (n = 3) . | Anti–PD-(L)1–naive HL∗ (n = 21) . | Anti–PD-(L)1–progressed HL∗ (n = 20) . | DLBCL (n = 15) . | |
| Ongoing treatment, n (%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Discontinued treatment, n (%) | 2 (100.0) | 2 (100.0) | 4 (100.0) | 3 (100.0) | 21 (100.0) | 20 (100.0) | 15 (100.0) |
| Disease progression | 1 (50.0) | 2 (100.0) | 4 (100.0) | 2 (66.7) | 2 (9.5) | 12 (60.0) | 14 (93.3) |
| Study drug toxicity | 0 | 0 | 0 | 0 | 3 (14.3) | 3 (15.0) | 0 |
| Patient request | 0 | 0 | 0 | 0 | 1 (4.8) | 0 | 1 (6.7) |
| Withdrew consent | 0 | 0 | 0 | 0 | 1 (4.8) | 1 (5.0) | 0 |
| Maximum clinical benefit† | 0 | 0 | 0 | 0 | 5 (23.8)‡ | 1 (5.0)§ | 0 |
| No longer met study criteria | 0 | 0 | 0 | 0 | 0 | 1 (5.0) | 0 |
| Completed treatment per protocol | 0 | 0 | 0 | 0 | 4 (19.0) | 1 (5.0) | 0 |
| Other | 1 (50.0) | 0 | 0 | 1 (33.3) | 5 (23.8) | 1 (5.0) | 0 |
| Discontinued study, n (%) | 1 (50.0) | 2 (100.0) | 0 | 2 (66.7) | 4 (19.0) | 5 (25.0) | 14 (93.3) |
| Withdrew consent | 0 | 0 | 0 | 0 | 2 (9.5) | 1 (5.0) | 2 (13.3) |
| Lost to follow-up | 0 | 0 | 0 | 1 (33.3) | 0 | 0 | 0 |
| Death | 1 (50.0) | 2 (100.0) | 0 | 0 | 1 (4.8) | 3 (15.0) | 9 (60.0) |
| Other | 0 | 0 | 0 | 1 (33.3) | 1 (4.8) | 1 (5.0) | 3 (20.0) |
| . | Relatlimab monotherapy (240 mg; part B) . | Nivolumab plus relatlimab (240 mg/160 mg; part D) . | |||||
|---|---|---|---|---|---|---|---|
| CLL (n = 2) . | DLBCL (n = 2) . | IL (n = 4) . | HL∗ (n = 3) . | Anti–PD-(L)1–naive HL∗ (n = 21) . | Anti–PD-(L)1–progressed HL∗ (n = 20) . | DLBCL (n = 15) . | |
| Ongoing treatment, n (%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Discontinued treatment, n (%) | 2 (100.0) | 2 (100.0) | 4 (100.0) | 3 (100.0) | 21 (100.0) | 20 (100.0) | 15 (100.0) |
| Disease progression | 1 (50.0) | 2 (100.0) | 4 (100.0) | 2 (66.7) | 2 (9.5) | 12 (60.0) | 14 (93.3) |
| Study drug toxicity | 0 | 0 | 0 | 0 | 3 (14.3) | 3 (15.0) | 0 |
| Patient request | 0 | 0 | 0 | 0 | 1 (4.8) | 0 | 1 (6.7) |
| Withdrew consent | 0 | 0 | 0 | 0 | 1 (4.8) | 1 (5.0) | 0 |
| Maximum clinical benefit† | 0 | 0 | 0 | 0 | 5 (23.8)‡ | 1 (5.0)§ | 0 |
| No longer met study criteria | 0 | 0 | 0 | 0 | 0 | 1 (5.0) | 0 |
| Completed treatment per protocol | 0 | 0 | 0 | 0 | 4 (19.0) | 1 (5.0) | 0 |
| Other | 1 (50.0) | 0 | 0 | 1 (33.3) | 5 (23.8) | 1 (5.0) | 0 |
| Discontinued study, n (%) | 1 (50.0) | 2 (100.0) | 0 | 2 (66.7) | 4 (19.0) | 5 (25.0) | 14 (93.3) |
| Withdrew consent | 0 | 0 | 0 | 0 | 2 (9.5) | 1 (5.0) | 2 (13.3) |
| Lost to follow-up | 0 | 0 | 0 | 1 (33.3) | 0 | 0 | 0 |
| Death | 1 (50.0) | 2 (100.0) | 0 | 0 | 1 (4.8) | 3 (15.0) | 9 (60.0) |
| Other | 0 | 0 | 0 | 1 (33.3) | 1 (4.8) | 1 (5.0) | 3 (20.0) |
BOR, best overall response; SD, stable disease.
Most were classic HL; 2 patients with nodular lymphocyte–predominant HL were included in part D (1 in PD-(L)1–progressed and 1 in PD-(L)1–naive).
Maximum clinical benefit was per investigator assessment.
BOR of PR (3) and SD (2) was observed among 5 patients with anti–PD-(L)1–naive HL with maximum clinical benefit.
BOR of SD (1) was observed among 1 patient with anti–PD-(L)1–progressed HL with maximum clinical benefit.